NCT03519230 2026-03-16
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
BeOne Medicines
Phase 3 Active not recruiting
Clinical Trials
29 trialsNCT04164199 2026-03-16
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
BeOne Medicines
Phase 3 Enrolling by invitation
NCT03749187 2026-03-13
PNOC017
University of California, San Francisco
Phase 1 Active not recruiting
NCT05494580 2026-03-10
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
Sun Yat-sen University
Phase 1/2 Completed
NCT05038839 2025-11-20
Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04614909 2025-02-28
Study of Pamiparib in Newly Diagnosed and rGBM
St. Joseph's Hospital and Medical Center, Phoenix
Phase EARLY_PHASE1 Active not recruiting
NCT03150862 2025-02-04
A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
BeiGene
Phase 1/2 Completed
NCT03333915 2025-02-04
Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors
BeiGene
Phase 1/2 Completed
NCT03914742 2025-01-14
BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT02361723 2024-12-27
Phase 1a/1b BGB-290 for Advanced Solid Tumors.
BeiGene
Phase 1 Completed
NCT05652283 2024-11-27
Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
Anhui Provincial Cancer Hospital
Phase 2 Active not recruiting
NCT06692491 2024-11-18
SPRING
Peking University Shenzhen Hospital
Phase 2 Not yet recruiting
NCT03427814 2024-10-26
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
BeiGene
Phase 2 Completed
NCT03575065 2024-10-26
Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
BeiGene
Phase 2 Completed
NCT03994211 2024-10-26
Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer
BeiGene
Phase 1 Completed
NCT06387056 2024-04-26
SEGNO
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT05489926 2024-01-26
A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT04774406 2023-06-06
Arterial Hypertension Related to PARP Inhibitors (ArteRIB)
University Hospital, Caen
Completed
NCT04603365 2023-05-17
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT04985721 2023-03-15
IMPARP-HRD
Peter MacCallum Cancer Centre, Australia
Phase 2 Unknown
NCT05376722 2023-01-05
A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT05669768 2023-01-03
Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy
Sun Yat-sen University
Phase 2 Unknown
NCT05483543 2022-08-02
Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy
Fudan University
Phase 2 Unknown
NCT04796454 2022-06-01
PAMICC
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT05327621 2022-04-14
Pamiparib in mCRPC With HRD or BRCA1/2 Mutation
Sun Yat-sen University
Phase 2 Unknown
NCT02660034 2021-12-06
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
BeiGene
Phase 1 Completed
NCT03712930 2021-11-17
Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency
BeiGene
Phase 2 Terminated
NCT04774627 2021-09-23
Pancytopenia Related to PARP Inhibitors (PancytoRIB)
University Hospital, Caen
Completed
NCT03933761 2021-08-10
PRECISE
Australia New Zealand Gynaecological Oncology Group
Phase 2 Withdrawn